The Claim
Urolithin A treatment in mice with HFpEF is associated with remodeling of the gut microbiome, including suppression of ceramide-producing bacterial genera (e.g., Bacteroides, Parabacteroides) and reduction in circulating ceramide species, suggesting a gut–heart axis mechanism contributing to reduced lipotoxic stress.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice with heart failure with preserved ejection fraction, Urolithin A alters gut bacteria to reduce levels of ceramide-producing species and lowers ceramide in the blood, which is linked to decreased lipotoxic stress.
See the scientific wording
Urolithin A treatment in HFpEF mice is associated with remodeling of the gut microbiome, including suppression of ceramide-producing bacterial genera (e.g., Bacteroides, Parabacteroides) and reduction in circulating ceramide species, suggesting a gut–heart axis mechanism contributing to reduced lipotoxic stress.
Urolithin A improves the heart's energy supply by cleaning up damaged mitochondria in heart cells, while also changing gut bacteria to stop them from making harmful fat molecules. These fat molecules, when reduced, prevent the heart from becoming stiff and scarred, allowing it to pump more efficiently.
What the research says
1 studyIn mice with a type of heart failure, a compound called urolithin A changed their gut bacteria in a way that lowered harmful fat molecules in the blood, which helped the heart work better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.